NCT03203356

Brief Summary

To evaluate in children affected by idiopathic GHD the adrenal function both at baseline and after 6 and 12 months of GH treatment.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started May 2016

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 30, 2016

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2017

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

May 26, 2017

Completed
4 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2017

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 29, 2017

Completed
Last Updated

June 29, 2017

Status Verified

June 1, 2017

Enrollment Period

11 months

First QC Date

May 26, 2017

Last Update Submit

June 27, 2017

Conditions

Keywords

growth hormonechildrenadrenal function

Outcome Measures

Primary Outcomes (2)

  • Evaluation of adrenal function in GHD children at baseline and in control group

    We will evaluate through insulin tolerance test the response of serum cortisol levels in GHD children at diagnosis (before start of GH therapy) and in controls subjects

    baseline

  • Change in adrenal function in GHD children during GH therapy

    We will evaluate through insulin tolerance test the response of serum cortisol levels in GHD children after 6 and 12 months of GH therapy

    6 and 12 months

Study Arms (2)

GHD children

about 30 prepubertal children affected by overt idiopathic GHD

Drug: growth hormone

controls

about 30 prepubertal children with constitutional short stature without endocrine disease

Interventions

Children with a diagnosis of GHD will practice GH replacement therapy in line with normal clinical practice and international guidelines. Controls will be evaluated just at baseline.

GHD children

Eligibility Criteria

Age5 Years - 12 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

30 consecutive children with short stature and overt idiopathic GHD and 30 children with constitutional short stature without endocrine disease

You may qualify if:

  • prepubertal children with overt idiopathic growth hormone deficiency

You may not qualify if:

  • Children with organic growth hormone deficiency or under treatment with glucocorticoids

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Endocrinology - University of Palermo

Palermo, 90127, Italy

Location

MeSH Terms

Interventions

Growth Hormone

Intervention Hierarchy (Ancestors)

Pituitary Hormones, AnteriorPituitary HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPeptidesAmino Acids, Peptides, and Proteins

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Prof. Carla Giordano

Study Record Dates

First Submitted

May 26, 2017

First Posted

June 29, 2017

Study Start

May 30, 2016

Primary Completion

May 1, 2017

Study Completion

May 30, 2017

Last Updated

June 29, 2017

Record last verified: 2017-06

Data Sharing

IPD Sharing
Will not share

IPD will be available just for our study

Locations